Autor der Publikation

Bitte wählen Sie eine Person um die Publikation zuzuordnen

Um zwischen Personen mit demselben Namen zu unterscheiden, wird der akademische Grad und der Titel einer wichtigen Publikation angezeigt. Zudem lassen sich über den Button neben dem Namen einige der Person bereits zugeordnete Publikationen anzeigen.

 

Weitere Publikationen von Autoren mit dem selben Namen

Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer, , , , , , , , und . The FEBS Journal, (März 2021)A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic, , , , , , , , , und 7 andere Autor(en). JCO Clinical Cancer Informatics, (2019)A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic., , , , , , , , , und 7 andere Autor(en). JCO clinical cancer informatics, (April 2019)An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution, , , , , , , , , und 12 andere Autor(en). Cell death & differentiation, 29 (4): 806-817 (2022)Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711, , , , , , , , und . Cell death and differentiation, 25 (11): 1952-1966 (2018)Exploratory multiplex tissue image analysis of the impact of heterogeneity in the microenvironment of primary colorectal cancer on apoptosis markers in patients, , , , , , , , , und 7 andere Autor(en). Proceedings: AACR Annual Meeting 2019, 79, 13, Suppl., Seite LB-088. Philadelphia, Pa., AACR, (2019)Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer, , , , , , , , , und . The FEBS journal, 288 (18): 5374-5388 (2021)A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer, , , , , , , , , und 20 andere Autor(en). Clinical cancer research, 23 (5): 1200-1212 (2017)RALB GTPase : A critical regulator of DR5 cell surface expression and TRAIL sensitivity in RAS mutant colorectal cancer, , , , , , , , , und 4 andere Autor(en). Proceedings: AACR Annual Meeting 2019, 79, 13, Suppl., Seite 5103. Philadelphia, Pa., AACR, (2019)RALB GTPase : a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer, , , , , , , , , und 9 andere Autor(en). Cell death & disease, (2020)